Treatment guidelines for acquired haemophilia by Huth-Kühne et al.

How do you manage bleeding events in patients who generally do not have a prior history of a bleeding disorder but present with spontaneous bleeding and an unexpected prolonged activated partial thromboplastin time (aPTT)?

To improve the care of patients with acquired haemophilia A, an international expert panel of clinicians, all of whom were experienced in the management of patients with acquired haemophilia A, provided a set of practice guidelines based on their collective clinical experience in treating such patients.

The consensus practice guidelines from Huth-Kühne, et al. were published in the journal Haematologica in 2009 and include an algorithm that focuses on when to initiate diagnosis of patients, inhibitor eradication and treatment of patients with bypassing agents. These guidelines recommend first-line therapy with bypassing agents to control acute bleeding and prophylactic use of bypassing agents prior to minor and major invasive procedures.1

Reference

  1. 1. Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009:94(4):566-575.

Rapid onset and sustained activity

FEIBA stops bleeds quickly and offers a long dosing interval. Read more

Proven efficacy

Discover the efficacy of FEIBA in both on-demand and prophylaxis treatment. Read more

Dosing FEIBA

Learn how to dose FEIBA. Read more